Whole-genome characterization of chemoresistant ovarian cancer

Nature

Volumn 521, Issue 7553, 2015, Pages 489-494

  Patch, Ann Marie ^a,b   Christie, Elizabeth L ^c   Etemadmoghadam, Dariush ^c,d   Garsed, Dale W ^c   George, Joshy ^e   Fereday, Sian ^c   Nones, Katia ^a,b   Cowin, Prue ^c   Alsop, Kathryn ^c   Bailey, Peter J ^a,f   Kassahn, Karin S ^a,g   Newell, Felicity ^a   Quinn, Michael C J ^a,b   Kazakoff, Stephen ^a,b   Quek, Kelly ^a   Wilhelm Benartzi, Charlotte ^h   Curry, Ed ^h   Leong, Huei San ^c   Hamilton, Anne ^c,d,i   Mileshkin, Linda ^c,d   Au Yeung, George ^c   Kennedy, Catherine ^j   Hung, Jillian ^j   Chiew, Yoke Eng ^j   Harnett, Paul ^j   Friedlander, Michael ^k   Quinn, Michael ^a   Pyman, Jan ⁱ   Cordner, Stephen ^l   O'Brien, Patricia ^l   Leditschke, Jodie ^l   Young, Greg ^l   Strachan, Kate ^l   Waring, Paul ^d   Azar, Walid ^c   Mitchell, Chris ^c   Traficante, Nadia ^c   Hendley, Joy ^c   Thorne, Heather ^c   Shackleton, Mark ^c,d   Miller, David K ^a   Arnau, Gisela Mir ^c   Tothill, Richard W ^c,d   Holloway, Timothy P ^c   Semple, Timothy ^c   Harliwong, Ivon ^a   Nourse, Craig ^a   Nourbakhsh, Ehsan ^a   Manning, Suzanne ^a   Idrisoglu, Senel ^a   Bruxner, Timothy J C ^a   Christ, Angelika N ^a   Poudel, Barsha ^a   Holmes, Oliver ^a,d   Anderson, Matthew ^a   Leonard, Conrad ^a,b   Lonie, Andrew ^m   Hall, Nathan ⁿ   Wood, Scott ^a,b   Taylor, Darrin F ^a   Xu, Qinying ^a,b   Lynn Fink, J ^a   Waddell, Nick ^a   Drapkin, Ronny ^o   Stronach, Euan ^h   Gabra, Hani ^h   Brown, Robert ^h   Jewell, Andrea ^p   Nagaraj, Shivashankar H ^a   Markham, Emma ^a   Wilson, Peter J ^a   Ellul, Jason ^c   McNally, Orla ^j   Doyle, Maria A ^c   Vedururu, Ravikiran ^c   Stewart, Collin ^q   Lengyel, Ernst ^p   Pearson, John V ^a,b   Waddell, Nicola ^a,b   Defazio, Anna ^j   Grimmond, Sean M ^a,f   Bowtell, David D L ^c,d,h   more..

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e JACKSON LABORATORY   (United States)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g Technology Advancement Unit Genetics and Molecular Pathology SA Pathology   (Australia)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ ROYAL WOMEN'S HOSPITAL   (Australia)

^j UNIVERSITY OF SYDNEY   (Australia)

^k UNIVERSITY OF NEW SOUTH WALES   (Australia)

^l VICTORIAN INSTITUTE OF FORENSIC MEDICINE   (Australia)

^m Crown Princess Mary Cancer Centre University of Sydney at Westmead Hospital ^*  (Australia)

ⁿ LA TROBE UNIVERSITY   (Australia)

^o DANA FARBER CANCER INSTITUTE   (United States)

^p UNIVERSITY OF CHICAGO   (United States)

^q UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; DNA; DOXORUBICIN; ETOPOSIDE; MULTIDRUG RESISTANCE PROTEIN 1; NF1 PROTEIN; OLAPARIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAD51B PROTEIN; RB1 PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; CCNE1 PROTEIN, HUMAN; CYCLIN E; DNA BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN; ONCOPROTEIN; PTEN PROTEIN, HUMAN; RAD51B PROTEIN, HUMAN; RETINOBLASTOMA PROTEIN;

CANCER; CHEMOTHERAPY; GENETIC ANALYSIS; GENOME; GENOMICS; WOMENS HEALTH;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DNA DETERMINATION; DNA METHYLATION; EXOME; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE INACTIVATION; GENE LOSS; GENE OVEREXPRESSION; GENE SEQUENCE; GENE STRUCTURE; GENETIC VARIABILITY; GENOME ANALYSIS; GERMLINE MUTATION; HETEROZYGOSITY; HIGH GRADE SEROUS OVARIAN CANCER; HOMOLOGOUS RECOMBINATION; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MISMATCH REPAIR; OVARY CANCER; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOMATIC MUTATION; COHORT ANALYSIS; CYSTADENOCARCINOMA, SEROUS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN GENOME; MUTAGENESIS; NUCLEOTIDE SEQUENCE; OVARIAN NEOPLASMS; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

COHORT STUDIES; CYCLIN E; CYSTADENOCARCINOMA, SEROUS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, NEUROFIBROMATOSIS 1; GENOME, HUMAN; GERM-LINE MUTATION; HUMANS; MUTAGENESIS; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PROMOTER REGIONS, GENETIC; PTEN PHOSPHOHYDROLASE; RETINOBLASTOMA PROTEIN;

EID: 84930638395     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14410     Document Type: Article

References (62)

1. Vaughan, S. et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nature Rev. Cancer 11, 719-725 (2011).
2. Ahmed, A. A. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221, 49-56 (2010).
3. The Cancer Genome Atlas Research Network. Integrated genomic analysis of ovarian cancer. Nature 474, 609-615 (2011).
4. Gorringe, K. L. et al. High-resolutionsinglenucleotide polymorphismarray analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin. Cancer Res. 13, 4731-4739 (2007).
5. Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nature Genet. 45, 1127-1133 (2013).
6. Mukhopadhyay, A. et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin. Cancer Res. 16, 2344-2351 (2010).
7. Bashashati, A. et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J. Pathol. 231, 21-34 (2013).
8. Castellarin,M. et al. Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease. J. Pathol. 229, 515-524 (2013).
9. Cowin, P. A. et al. LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res. 72, 4060-4073 (2012).
10. Popova, T. et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 72, 5454-5462 (2012).
11. George, J. et al. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin. Cancer Res. 19, 3474-3484 (2013).
12. Clarke, B. et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod. Pathol. 22, 393-402 (2009).
13. Soslow, R. A. et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod. Pathol. 25, 625-636 (2012).
14. Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27-40 (2011).
15. Kinsella, M. & Bafna, V. Combinatorics of the breakage-fusion-bridge mechanism. J. Comput. Biol. 19, 662-678 (2012).
16. Baca, S. C. et al. Punctuated evolution of prostate cancer genomes. Cell 153, 666-677 (2013).
17. Rausch, T. et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148, 59-71 (2012).
18. Nones, K. et al. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int. J. Cancer 135, 1110-1118 (2014).
19. Salzman, J. et al. ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma. PLoS Biol. 9, e1001156 (2011).
20. Kannan, K. et al. CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade serous ovarian carcinoma. PLoS Genet. 10, e1004216 (2014).
21. Alexandrov, L. B. et al. Signatures ofmutational processes in humancancer. Nature 500, 415-421 (2013).
22. Etemadmoghadam, D. et al. Integrated genome-wide DNA copy number and expression analysis identifies distinctmechanisms of primary chemoresistance in ovarian carcinomas. Clin. Cancer Res. 15, 1417-1427 (2009).
23. Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198-5208 (2008).
24. Verhaak, R. G. et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J. Clin. Invest. 123, 517-525 (2013).
25. Norquist, B. et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29, 3008-3015 (2011).
26. Lengyel, E. Ovarian cancer development and metastasis. Am. J. Pathol. 177, 1053-1064 (2010).
27. Swisher, E. M. et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581-2586 (2008).
28. Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mousemodel of pancreatic cancer. Science 324, 1457-1461 (2009).
29. Geisler, J. P., Hatterman-Zogg,M. A., Rathe, J. A.& Buller, R. E. Frequency of BRCA1 dysfunction in ovarian cancer. J. Natl. Cancer Inst. 94, 61-67 (2002).
30. Meier,B. et al. C. elegans whole-genomesequencing revealsmutational signatures related to carcinogens and DNA repair deficiency. Genome Res. 24, 1624-1636 (2014).
31. Edwards, S. L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111-1115 (2008).
32. Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116-1120 (2008).
33. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
34. Vergote, I. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363, 943-953 (2010).
35. Murray, S., Briasoulis, E., Linardou, H., Bafaloukos, D. & Papadimitriou, C. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat. Rev. 38, 890-903 (2012).
36. Binkhathlan, Z. & Lavasanifar, A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr. Cancer Drug Targets 13, 326-346 (2013).
37. Lhommé, C. et al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J. Clin. Oncol. 26, 2674-2682 (2008).
38. Jaspers, J. E. et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 3, 68-81 (2013).
39. Johnson, B. E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343, 189-193 (2014).
40. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
41. Rustin, G. J. et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int. J. Gynecol. Cancer 21, 419-423 (2011).
42. Friedlander, M. L. et al. Clinical trials of palliative chemotherapy in platinumresistant or-refractory ovarian cancer: time to think differently J. Clin. Oncol. 31, 2362 (2013).
43. Popova, T. et al. Genome Alteration Print (GAP): a tool to visualize andminecomplex cancer genomic profiles obtained by SNP arrays. Genome Biol. 10, R128 (2009).
44. Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
45. Song, S. et al. qpure: A tool to estimate tumor cellularity fromgenome-wide singlenucleotide polymorphism profiles. PLoS ONE 7, e45835 (2012).
46. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
47. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
48. DeLuca, D. S. et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 28, 1530-1532 (2012).
49. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification fromRNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
50. Wang, K. et al. MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res. 38, e178 (2010).
51. Wilhelm-Benartzi, C. S. et al. Review of processing and analysis methods for DNA methylation array data. Br. J. Cancer 109, 1394-1402 (2013).
52. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118-127 (2007).
53. Kassahn, K. S. et al. Somatic pointmutation calling in low cellularity tumors. PLoS ONE 8, e74380 (2013).
54. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
55. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
56. Gundem, G. et al. IntOGen: integration and data mining of multidimensional oncogenomic data. Nature Methods 7, 92-93 (2010).
57. Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865-2871 (2009).
58. Robinson, J. T. et al. Integrative genomics viewer. Nature Biotechnol. 29, 24-26 (2011).
59. Ojesina, A. I. et al. Landscape of genomic alterations in cervical carcinomas. Nature 506, 371-375 (2014).
60. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012).
61. Korbel, J. O. & Campbell, P. J. Criteria for inference of chromothripsis in cancer genomes. Cell 152, 1226-1236 (2013).
62. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012).